Icon plc Aktie
Icon plc Aktie
Was spricht für und gegen Icon plc in den nächsten Jahren?
Pro
Kontra
Rendite von Icon plc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Icon plc | -2,86 % | 0,06 % | 12,04 % | -19,35 % | -22,34 % | -18,57 % | - |
| Alkermes plc | 0,81 % | -0,79 % | -7,41 % | -14,38 % | -10,71 % | 2,69 % | 60,26 % |
| Ironwood Pharmaceuticals | 0,64 % | -5,42 % | 96,25 % | -1,26 % | -25,24 % | -72,65 % | -67,96 % |
| Novocure Ltd | 2,37 % | -6,22 % | 2,87 % | -58,65 % | -64,29 % | -86,01 % | -91,45 % |
Kommentare
News
3 Healthcare Pathbreakers With Long-Term Tailwinds
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the





